Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT01377558
Other study ID # Gi-03-2011
Secondary ID
Status Active, not recruiting
Phase N/A
First received June 9, 2011
Last updated June 22, 2011
Start date April 2011
Est. completion date June 2012

Study information

Verified date April 2011
Source University of Giessen
Contact n/a
Is FDA regulated No
Health authority Germany: Ethics Commission
Study type Interventional

Clinical Trial Summary

The purposes of the study are

- to determine which kind of supervised exercise intervention (aerobic endurance training versus strength endurance training versus combined aerobic endurance and strength endurance training) is more effective in improving the metabolic parameters in typ 2 diabetes patients

- to investigate what kind of intervention is more successful in reduction of concomitant diseases and improving quality of life

- to assess what kind of intervention induces highest effects in long term persistence of these positive changes


Description:

Meta-analyses which evaluated the effects of structured exercise programs in patients with type 2 diabetes demonstrate that regular physical activity improves glycosylated haemoglobin (König et al.: Resistance Exercise and Type 2 Diabetes Mellitus, Deutsche Zeitschrift für Sportmedizin Jahrgang 62, Nr. 1 (2011): 5-9). Sigal et al. proved that either aerobic or resistance training alone improved glycemic control in type 2 diabetes, but the improvements are greatest with combined aerobic and resistance training (Sigal, RJ, et al.: Effects of Aerobic Training, Resistance Training, or Both on Glycemic Control in Type 2 Diabetes, Ann Intern Med. 2007 Sep 18;147(6):357-69).

Therefore, aim of the current study is to compare the effects of aerobic endurance training or resistance endurance training or the combination of aerobic endurance training and resistance endurance training in diabetes type 2 patients without any other lifestyle or dietary interventions.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 100
Est. completion date June 2012
Est. primary completion date November 2011
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- diagnoses of type 2 diabetes (ADA criteria)

- admitted diabetes treatments will be diet and oral hypoglycemic agents

Exclusion Criteria:

- sports intervention >60 minutes per week

- medical conditions

- preproliferative or proliferative retinopathy

- instable coronary heart disease

- inability to perform the scheduled physical activity programs

- acute clinically significant intercurrent diseases

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment


Intervention

Other:
Aerobic endurance training intervention
The aerobic endurance training group will use cardiovascular training devices week 1-4: 15 minutes warm up (group) 15 minutes intervention at 80-100% vAT two times per week week 5-13: 15 minutes warm up (group) 30 minutes intervention at 95-110% vAT two times per week week 14-26: 15 minutes warm up (group) 45 minutes intervention at 95-110% vAT two times per week
Strength endurance training intervention
The strength endurance training intervention group will perform eight exercises on weight machines (Milon circuit training- 60 seconds activity, 30 seconds break) week 1-4: 15 minutes warm up (group) 1 session resistance training intensity 3 (Buskies) two times per week week 5-13: 15 minutes warm up (group) 2 sessions resistance training intensity 5 (Buskies) two times per week week 14-26: 15 minutes warm up (group) 3 sessions resistance training intensity 5 (Buskies) two times per week
Combined aerobic endurance and strength endurance training
week 1-4: 15 minutes warm up (group) 15 minutes intervention at 80-100% vAT once per week and 15 minutes warm up (group) 1 session resistance training intensity 3 (Buskies) once per week week 5-13: 15 minutes warm up (group) 15 minutes intervention at 95-110% vAT and 1 session resistance training intensity 5 (Buskies) two times per week week 14-26: 15 minutes warm up (group) 30 minutes intervention at 95-110% vAT and 1 session resistance training intensity 5 (Buskies) once a week and 15 minutes warm up (group) 15 minutes intervention at 95-110% vAT and 2 sessions resistance training intensity 5 (Buskies) once a week

Locations

Country Name City State
Germany University of Giessen Giessen Hessen
Germany Sportpark Zwickau, Glauchau, Meerane Zwickau Sachsen

Sponsors (2)

Lead Sponsor Collaborator
University of Giessen Hannover Medical School

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in HbA1c-level (haemoglobin A1c) 6 months No
Secondary Change in HOMA-Index 3 and 6 months No
Secondary Change in beta-cell-function Measured by OGTT (Oral Glucose Tolerance Test) 3 and 6 months No
Secondary Change in fasting plasma glucose levels 3 and 6 months No
Secondary Change in total cholesterol levels 3 and 6 months No
Secondary Change in HDL-cholesterol levels 3 and 6 months No
Secondary Change in LDL-cholesterol levels 3 and 6 months No
Secondary Change in triglyceride levels 3 and 6 months No
Secondary Change in antidiabetic medications Class and dosage of blood-glucose lowering drugs are recorded before, after 3 and 6 months 3 and 6 months No
Secondary Change in inflammation markers CrP, blood count, interleukinstatus, cytokinstatus 3 and 6 months No
Secondary Change in body weight 3 and 6 months No
Secondary Change in body composition by Bio-impedance analysis, waist to hip ratio, range of thigh 3 and 6 months No
Secondary Change in strength by Dr. Wolff Back Check 3 and 6 months No
Secondary Change of maximum heart rate Measured by an incremental exercise test 3 and 6 months No
Secondary Change of peak oxygen uptake Measured by an incremental exercise test 3 and 6 months No
Secondary Change of vAT (ventilatory anaerobic threshold) Measured by an incremental exercise test 3 and 6 months No
Secondary Change in blood pressure 3 and 6 months No
Secondary Change in renal function Creatininlevel, Albuminlevel (urine), Telomere length 3 and 6 months No
Secondary Change in concentration by d2-test 3 and 6 months No
Secondary Change in quality of life by questionnaire: SF-12, EQ5 3 and 6 months No
Secondary Change of nutrition by questionnaire: FEV, FFQ 3 and 6 months No
Secondary Change in voluntary physical activity meassured by pedometer (one week) 3 and 6 months No
Secondary Change of cardiac output by Impedance cardiography by Task Force Monitor 3 and 6 months No
Secondary Change of barorezeptorsensitivity by Task Force Monitor 3 and 6 months No
Secondary Change in carotid-Intima-Media-Thickness 3 and 6 months No
Secondary Change in aortic pulse-wave velocity 3 and 6 months No
Secondary Change in central aortic pressure 3 and 6 month No
Secondary Change in endothelial dysfunction 3 and 6 months No
Secondary Change of parodontitis 3 and 6 months No
Secondary Follow up of all parameters mentioned above Follow up after 12 months (6 months after completing the exercise intervention) without any supervised intervention after 12 months No
See also
  Status Clinical Trial Phase
Completed NCT05219994 - Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum N/A
Completed NCT04056208 - Pistachios Blood Sugar Control, Heart and Gut Health Phase 2
Completed NCT02284893 - Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone Phase 3
Completed NCT04274660 - Evaluation of Diabetes and WELLbeing Programme N/A
Active, not recruiting NCT05887817 - Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR) Phase 4
Active, not recruiting NCT05566847 - Overcoming Therapeutic Inertia Among Adults Recently Diagnosed With Type 2 Diabetes N/A
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Completed NCT04965506 - A Study of IBI362 in Chinese Patients With Type 2 Diabetes Phase 2
Recruiting NCT06115265 - Ketogenic Diet and Diabetes Demonstration Project N/A
Active, not recruiting NCT03982381 - SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes Phase 4
Completed NCT04971317 - The Influence of Simple, Low-Cost Chemistry Intervention Videos: A Randomized Trial of Children's Preferences for Sugar-Sweetened Beverages N/A
Completed NCT04496154 - Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry "Bad Cholesterol" in the Blood N/A
Completed NCT04023539 - Effect of Cinnamomum Zeylanicum on Glycemic Levels of Adult Patients With Type 2 Diabetes N/A
Recruiting NCT05572814 - Transform: Teaching, Technology, and Teams N/A
Enrolling by invitation NCT05530356 - Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
Completed NCT03960424 - Diabetes Management Program for Hispanic/Latino N/A
Completed NCT04097600 - A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets Phase 1
Completed NCT05378282 - Identification of Diabetic Nephropathy Biomarkers Through Transcriptomics
Active, not recruiting NCT06010004 - A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Phase 3
Completed NCT03653091 - Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes N/A